gp120蛋白多肽抗体的设计、制备与鉴定-东南大学学报医学版

gp120蛋白多肽抗体的设计、制备与鉴定

单位：南京大学医学院公共健康医学中心, 江苏南京 210093

分类号：TQ936.13

出版年·卷·期（页码）：2012·31·第三期（286-290）

摘要：

目的:设计多肽免疫原,制备针对中国流行株B’亚型人类免疫缺陷病毒一型(HIV-1)gp120蛋白的抗血清和相应单克隆抗体。方法:通过蛋白抗原设计,设计出免疫原多肽,将多肽欧联载体蛋白免疫小鼠,制备小鼠多克隆抗血清和单克隆抗体;用ELISA实验、蛋白免疫印迹鉴定其活性和表位。结果:成功制备了能结合gp120蛋白的小鼠多克隆抗血清,并且获得4株分泌特异性抗免疫原的IgG1亚型的单克隆细胞株。结论:蛋白抗原设计是成功的,该多肽能诱导结合蛋白的抗体,有可能成为针对艾滋病病毒中国流行株的多肽疫苗。

Objective: Peptide was induced poly-or mono-antibody against gp120 of subtype B’which prevails in China. Methods: Designed peptide was conjugated with carrier protein of KLH to induce poly-or mono-antibody. The antibody was characterized via ELISA or Western blotting. Results: Poly-antibody could bind with the protein of gp120, in addition, four monoclonal cell secreting the antibody of subtype IgG1 was obtained.Conclusion: The antigen design is successful, such designed peptide could induce antibody against protein containing the sequence of the peptide. Such peptide could be potential vaccine against the HIV-1 spreading in China.

参考文献：

[1] BHATTACHARYA M,NEOGI S B.Estimation of mortality due to AIDS—a review[J].Indian J Public Health,2008,52:21-27.
[2] HO D D,BIENIASZ P D.HIV-1 at 25[J].Cell,2008,133:561-565.
[3] ZOLLA-PAZNER S.Identifying epitopes of HIV-1 that induce protective antibodies[J].Nature Reviews Immunology,2004,4:199-210.
[4] ZOLLA-PAZNER S,COHEN S S,KRACHMAROV C,et al.Focusing the immune response on the V3 loop,a neutralizing epitope of the HIV-1 gp120 envelope[J].Virology,2008,372:233-246.
[5] ZOLLA-PAZNER S,CARDOZO T.Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design[J].Nature Reviews Immunology,2010,10:527-535.
[6] SHANG H,HAN X,SHI X,et al.Genetic and neutralization sensitivity of diverse HIV-1 env clones from chronically infected patients in china[J].J Biol Chem,2011,286:14531-14541.
[7] BAROUCH D H.Challenges in the development of an HIV-1 vaccine[J].Nature,2008,455:613-619.
[8] BURTON D R,DESROSIERS R C,DOMS R W,et al.HIV vaccine design and the neutralizing antibody problem[J].Nature Immunology,2004,5:233-236.
[9] BURTON D R,WEISS R A.AIDS/HIV.A boost for HIV vaccine design[J].Science,2010,329:770-773.
[10] ROBB M L.HIV vaccine development:past,present and future[J].IDrugs,2010,13:852-856.
[11] FISER A,SALI A.MODELLER:Generation and refinement of homology-based protein structure models.Macromolecular Crystallography[M].New York:Academic Press,2003:461.
[12] von der MALSBURG C.The what and why of binding:the modeler’s perspective[J].Neuron,1999,24:95-104.
[13] CHONG P,CHAN N,KANDIL A,et al.A strategy for rational design of fully synthetic glycopeptide conjugate vaccines[J].Infect Immun,1997,65:4918-4925.
[14] QI Y,ZHANG B Q,SHEN Z,et al.Candidate vaccine focused on a classical swine fever virus epitope induced antibodies with neutralizing activity[J].Viral Immunology,2009,22:205-213.
[15] 鲍海逊,夏梅,缪凤琴,等.SARS冠状病毒S蛋白基因片段的表达及其单克隆抗体的制备[J].东南大学学报:医学版,2009,28(1):18-21.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录